Clinical Trial Update: Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating GP chemotherapy plus tislelizumab in locoregionally advanced nasopharyngeal carcinoma. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED